Polar Capital Holdings’s Rhythm Pharmaceuticals RYTM Stock Holding History

Polar Capital Holdings’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$185M	Buy	1,663,632 +48,046	+3%	+$4.34M	0.44%	54
2026 Q1	$141M	Buy	1,615,586 +430,194	+36%	+$41.8M	0.5%	52
2025 Q4	$127M	Sell	1,185,392 -59,540	-5%	-$6.32M	0.49%	55
2025 Q3	$126M	Sell	1,244,932 -5,938	-0.5%	-$551K	0.61%	50
2025 Q2	$79M	Buy	1,250,870 +750,870	+150%	+$46M	0.41%	66
2025 Q1	$26.5M	Sell	500,000 -1,000,000	-67%	-$55.5M	0.16%	129
2024 Q4	$84M	Hold	1,500,000	–	–	0.47%	59
2024 Q3	$78.6M	Hold	1,500,000	–	–	0.37%	60
2024 Q2	$61.6M	Hold	1,500,000	–	–	0.36%	73
2024 Q1	$65M	Sell	1,500,000 -250,000	-14%	-$10.9M	0.34%	72
2023 Q4	$80.4M	Sell	1,750,000 -750,000	-30%	-$23.7M	0.49%	55
2023 Q3	$57.3M	Buy	2,500,000 +250,000	+11%	+$5.6M	0.42%	69
2023 Q2	$37.1M	Buy	2,250,000 +500,000	+29%	+$9.03M	0.19%	103
2023 Q1	$31.2M	Buy	1,750,000 +500,000	+40%	+$12.6M	0.2%	112
2022 Q4	$36.4M	Buy	1,250,000 +535,261	+75%	+$13.8M	0.29%	104
2022 Q3	$17.5M	Buy	+714,739	New	+$13.3M	0.11%	154

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Polar Capital Holdings's RYTM Position: Q2 2026 in Review

Polar Capital Holdings increased its Rhythm Pharmaceuticals (RYTM) stake by 3% in Q2 2026, buying an estimated $4.34M and bringing the position to 1,663,632 shares worth $185M. The position accounts for 0.44% of the portfolio, ranked #54.

Polar Capital Holdings first reported a position in RYTM in Q3 2022 and has held it in 16 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Polar Capital Holdings held 1,663,632 shares of Rhythm Pharmaceuticals worth $185M as of Q2 2026.
Polar Capital Holdings bought 48,046 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $4.34M.
Rhythm Pharmaceuticals made up 0.44% of Polar Capital Holdings's portfolio in Q2 2026, its #54 holding.
Polar Capital Holdings first reported a position in Rhythm Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.